Provider Attitudes and Practice Patterns of Obesity Management with Pharmacotherapy by Granara, Brittany
University of Vermont
ScholarWorks @ UVM
Graduate College Dissertations and Theses Dissertations and Theses
2017




Follow this and additional works at: https://scholarworks.uvm.edu/graddis
Part of the Medical Sciences Commons, and the Nursing Commons
This Thesis is brought to you for free and open access by the Dissertations and Theses at ScholarWorks @ UVM. It has been accepted for inclusion in
Graduate College Dissertations and Theses by an authorized administrator of ScholarWorks @ UVM. For more information, please contact
donna.omalley@uvm.edu.
Recommended Citation
Granara, Brittany, "Provider Attitudes and Practice Patterns of Obesity Management with Pharmacotherapy" (2017). Graduate College
Dissertations and Theses. 666.
https://scholarworks.uvm.edu/graddis/666
	  PROVIDER ATTITUDES AND PRACTICE PATTERNS OF OBESITY 









The Faculty of the Graduate College  
of 
The University of Vermont 
 
 
In Partial Fulfillment of the Requirements  
For the Degree of Master of Science 
Specializing in Nursing 
 








Defense Date: November 9, 2016 
Thesis Examination Committee: 
 
Jennifer S. Laurent, Ph.D., APRN, Advisor 
Jeremy S. Sibold, Ed.D., ATC, Chairperson 
Ellen C. Watson, APRN 
Cynthia J. Forehand, Ph.D., Dean of the Graduate College 
	  ABSTRACT 
Background and Purpose: More than one-third of American adults are obese. 
The prevalence of extreme obesity is rapidly rising. Nine medications are currently 
approved for weight loss yet they remain under utilized with the focus primarily on 
lifestyle modifications. The study’s objective was to determine current prescribing 
patterns and attitudes of weight loss medications in the management of obesity among 
primary care providers (PCPs).   
Methods: PCPs were surveyed to determine practice patterns, attitudes, barriers, 
and facilitators for prescribing weight loss medications.    
Conclusions: A total of 105 surveys were completed. 76% of all PCPs did not 
prescribe weight loss medications for long-term weight loss therapy and 58% of PCPs 
had negative perceptions of pharmacotherapy as a treatment. Significant differences 
existed between prescribing patterns and attitudes of advanced practice clinicians and 
physicians. Safety concerns were identified as the greatest barrier. Having 2+ 
comorbidities and severe obesity were identified as facilitators for prescribing weight loss 
medications. Under utilization of pharmacotherapy suggests that PCPs may not have 
sufficient knowledge about medication safety profiles and efficacy. Delaying treatment 
until patients have reached a high level of morbidity may be less efficacious than earlier 
treatment. 
Implications for Practice: Education regarding effectiveness and risks of weight 
loss medications for obesity management is needed and earlier interventions with 
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CHAPTER I: Introduction 
Overview of the Research Problem 
The prevalence of obesity in the United States (U.S.) is high. In 2011-2012, more 
than one-third (35% or 78.6 million) of American adults were obese (Ogden, Carroll, Kit, 
& Flegal, 2014). Although there have been no significant changes in obesity prevalence 
since 2003-2004, the number of individuals living with obesity remains at an all-time 
high. Furthermore, the prevalence of extreme obesity (body mass index [BMI] ≥40 
kg/m2) increased by 70% between 2000 and 2010 (Sturm & Hattori, 2013). Obesity is a 
substantial health concern, predisposing individuals to poor health outcomes caused by 
associated co-morbidities.  
Obesity substantially increases the risk of morbidity and mortality due to the wide 
range of accompanying co-morbidities. According to the Centers for Disease Control 
(CDC) obesity-related conditions comprise some of the leading causes of preventable 
death, including cardiovascular disease, stroke, type 2 diabetes, and certain types of 
cancer (CDC, 2016a). Overall, as BMI rises, the risk of multimorbidity (co-occurrence of 
multiple long-term diseases) increases in both men and women. The prevalence of 
multimorbidity in men and women with normal weight is 23% and 28% respectively, 
rising to 44% in men and 51% in women with extreme obesity (Booth, Prevost, & 
Gulliford, 2014). A weight loss of 5-10% of total baseline body weight can significantly 
reduce cardiovascular disease risk factors, including lowering blood pressure and blood 
cholesterol, as well as preventing or delaying the development of type 2 diabetes (CDC, 
2016b).  
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The direct and indirect costs attributed to obesity in the U.S. are staggering. While 
direct medical costs may include prevention, diagnostic, and treatment services 
associated with obesity and obesity-related diseases, indirect medical costs may include 
premature mortality, higher disability insurance premiums, and productivity loss due to 
obesity (Hammond & Levine, 2010). According to Finkelstein, Trogdon, Cohen, & Dietz 
(2009), the estimated annual medical cost attributable to obesity in the U.S. was $147 
billion. Overall, the annual medical burden of obesity has risen to almost 10 percent of all 
medical spending. The medical spending for obese individuals across all payers is nearly 
42%, or $1,429 higher than the spending for individuals who are normal-weight. 
Similarly in 2006, medical spending for obese beneficiaries cost Medicare over $600 per 
beneficiary per year more than normal-weight beneficiaries (Finkelstein et al., 2009). 
Despite the concerning obesity epidemic, appropriate and consistent management 
of obese individuals in primary care settings remains variable (Bleich, Pickett-Blakely, & 
Cooper, 2011; Shiffman et al., 2009). Current clinical guidelines from the U.S. 
Preventive Services Task Force recommend that all adult patients be screened for obesity 
and individuals with BMI ≥30kg/m2 should be offered or referred to intensive, 
multicomponent behavioral interventions (Moyer, 2012). Regardless of these 
recommendations, several cross-sectional studies have shown that not only are obese 
individuals not being consistently diagnosed, weight loss counseling by providers is also 
infrequent, inconsistent, and sub-optimal (Bleich, 2011, Shiffman, 2009; Smith, 2011). 
When weight loss counseling is incorporated into clinical practice, studies have found 
that lifestyle interventions are the foundation of primary care provider’s (PCP’s) 
counseling. Although pharmacotherapy and bariatric surgery are other available and 
	  	   3	  
effective weight loss interventions, they are often not included or rarely recommended to 
individuals suffering from obesity (Ferrante, Piasecki, Ohman-Strickland, & Crabtree, 
2009; Shiffman, 2009).  
Lifestyle interventions alone are not particularly successful in providing long-
term weight maintenance due to behavioral and environmental pressures as well as 
biological mechanisms induced by weight loss (Korner & Aronne, 2003; Rosenbaum, 
Hirsch, Gallagher, & Leibel, 2008). The addition of pharmacotherapy as an adjunct to 
traditional diet and exercise approaches has shown to be an effective treatment option for 
weight loss in obese individuals (Yanovski SZ & Yanovski JA, 2014). When combined 
with lifestyle interventions, weight loss medications have resulted in 5-10% weight loss 
(Gadde, 2011, Smith, 2010; Yanovski, 2014). While prior studies have examined factors 
influencing and barriers preventing weight loss counseling in primary care settings, little 
research has assessed PCPs’ practice patterns and attitudes around the use of weight loss 
medications. There is lack of current research examining the underlying reasons for 
limited pharmacotherapy use in weight loss counseling, despite its demonstrated efficacy.  
Purpose of the Study 
The purpose of this study was to examine prescribing patterns of currently 
available, Food and Drug Administration (FDA) approved weight loss medications 
among PCPs. A self-reported survey was used to evaluate prescribers’ current practice 
patterns and attitudes around their use of weight loss medications in obesity management.  
Theoretical Framework 
 The theoretical framework that guided this study was the Theory of Reasoned 
Action (TRA) (Fishbein & Ajzen, 1975). The theory was developed in the late 1960s and 
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later modified to the Theory of Planned Behavior. The relationship between beliefs, 
attitudes, intentions, and behavior are explained by the TRA. Under this theory, it is 
assumed that people are rational and make decisions based on available information. The 
theory posits that behavior is predicted by the individual’s intention to perform the 
behavior. In regards to the Theory of Planned Behavior, intention is the most important 
element of a person’s behavior. Intention is the individual’s readiness to perform a 
behavior as determined by their attitude toward the behavior, subjective norms, and 
perceived control of the behavior.  
 An individual’s attitude is formed based on their overall evaluation of performing 
the behavior and their beliefs about the behavior’s consequences. Attitude encompasses 
knowledge, feelings, beliefs, intentions, and perceptions. Conversely, subjective norms 
are the social pressures applied to an individual to perform or not perform a behavior. 
These pressures may influence the decision to perform a behavior by an inherent desire to 
conform to other’s opinions and to behave as others expect them to behave. Finally, 
perceived behavioral control is the perceived power an individual has over performing 
the behavior. Perceived control is influenced by the individual’s attitude and subjective 
norms. Typically, the individual’s perceived control and thus intent to perform the 
behavior will be greater if the attitude and subjective norm are positive.  
 The Theory of Reasoned Action helps explain providers’ behavior toward the use 
of weight loss medications for obese individuals. This study encompasses the 
components of this theory by assuming that providers’ intent to perform a behavior is 
based on their beliefs, attitudes, subjective norms, and perceived control. The TRA is 
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useful in determining the factors that predict a provider’s intentions to include 
pharmacotherapy in obesity care. 
Aims/Objective 
The objective of the current study was to determine current prescribing patterns 
and attitudes of weight loss medications in the management of obesity among PCPs. The 
study had three aims including, 1.) To determine why PCPs are or are not including 
weight loss medications in weight loss counseling, 2.) To determine what barriers exist 
around the use of weight loss medications in obesity management, and 3.) To determine 
under what circumstances PCPs are prescribing weight loss medications for obesity.  
Nurse Practitioner Core Competencies 
 Nurse practitioners can play a significant role in producing positive health 
outcomes for obese patients. As licensed independent practitioners, advanced practice 
nurses provide leadership in the translation of new knowledge into practice (Thomas et 
al., 2012). By seeking to better understand practice patterns and barriers regarding the use 
of effective treatment options for the management of obesity, nurse practitioners can 
implement the gained knowledge to provide improved and well-informed care to obese 
patients. Furthermore, nurse practitioners are responsible as health care providers to 
integrate ethical principles into their clinical decision-making (Thomas et al., 2012).  
Thus, they are ethically accountable for recognizing and informing obese patients of all 
available and effective treatment options. Nurse practitioners are in a position to be 
leaders in transforming health care delivery and providing high quality care to patients 
with complex conditions. Through this study, nurse practitioner core competencies were 
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achieved by integrating new knowledge into the care of adults living with obesity and its 
associated co-morbidities. 
Significance 
Understanding practice patterns, barriers, and PCP attitudes regarding the use of 
weight loss medications for obesity management can identify knowledge gaps and inform 
appropriate interventions for PCP education and training. Enhancing PCP skill and 
knowledge around effective adjunct treatment options for obesity care may result in more 
frequent pharmacotherapy use and thus greater long-term weight-loss maintenance and 
improved patient outcomes. Additionally, the information gained from this study may be 
helpful in the development and implementation of obesity treatment guidelines as they 
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CHAPTER II: Comprehensive Literature Review  
 
 This chapter presents the available research related to current obesity management 
practices, including the efficacy and use of available weight loss interventions.   
Interventions currently included in weight loss counseling and efficacy 
 
Available weight loss interventions include lifestyle modifications, 
pharmacological approaches, and surgical options. Currently, lifestyle modifications 
incorporating diet and physical activity remain the foundation of weight loss counseling 
in primary care settings for patients who are overweight and obese.  
Bleich et al. (2011) analyzed cross-sectional clinical encounter data from 
physician office visits to identify whether obese patients received weight-related 
counseling from their physician. Data on obese adults (n=2458) was obtained from the 
National Ambulatory Medical Care Survey (NAMCS). Researchers found that a third of 
the obese study sample received an obesity diagnosis, 17.6% received weight reduction 
counseling, 20.5% received exercise counseling, and 25.2% received diet counseling. 
Counseling about other weight loss interventions including obesity medication and 
surgery was not studied. Likewise, Shiffman et al. (2009) conducted a cross-sectional 
study evaluating what weight management interventions American adult patients 
(n=3500) reported receiving from physicians. Data was collected through a random-digit 
dialed telephone survey in 2005-2006. At the time of the study, 41.6% of respondents 
were normal weight, 35.9% overweight, and 22.5% obese, according to BMI. 
Respondents were asked a series of questions regarding the types of weight management 
interventions physicians had ever recommended to them. Ten recommended interventions 
were listed including being told about health problems associated with being overweight, 
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changing their diet, suggesting diet and exercise, stating diet and exercise are the only 
way to lose weight, prescribing weight loss medication, recommending over the counter 
weight loss products, suggesting bariatric surgery, providing reading material about 
weight loss, referral to dietitian/nutritionist, and suggesting a formal diet program. 
Twenty-eight percent of respondents (14.1% of obese respondents) denied ever being 
offered any of the listed interventions. The interventions most frequently reported 
included having a physician tell them about health problems associated with being 
overweight (48%) and suggesting diet and exercise (46.5%). Overall, only 4.0% of 
respondents (9.8% of obese respondents) reported receiving a prescription for weight loss 
medication. Bariatric surgery was recommended in 1.5% of participants. Both studies 
were limited by their cross-sectional nature. Additionally, reports of weight loss 
counseling were subjective and thus recall bias may have influenced study results by 
under or over-estimating weight-related counseling. 
While lifestyle modifications are recommended most frequently, diet and exercise 
have not proven to be effective for long-term weight loss success. Although many 
individuals are able to lose weight with diet, many go on to regain all or a majority of the 
weight lost (MacLean, Bergouignan, Cornier, & Jackman, 2011).	  Aside from behavioral 
and environmental factors, neurohormonal mechanisms have been identified as promoters 
of weight regain after weight loss caused by dietary restriction. In addition to reduced 
energy expenditure, restricting calories results in compensatory changes in the peripheral 
hormonal pathways including decreased levels of anorexogenic hormones, and increased 
levels of ghrelin leading to increased appetite (Rosenbaum, Hirsch, Gallagher, & Leibel, 
2008). The combination of decreased energy expenditure and changes in neurohormonal 
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status leads to increased food intake, restoration of fat cell mass, and thus weight regain 
(Korner & Aronne, 2003).  
Physical activity alone produces only modest reduction in body weight. Donnelly, 
Jacobsen, Heelan, Seip, & Smith (2000) studied the effects of continuous versus 
intermittent exercise on body weight and composition for 18 months in moderately obese 
females (n=22) who were previously sedentary. The continuous exercise group exercised 
3 times per week for 30 minutes at 60-75% of maximal aerobic capacity. The intermittent 
group walked briskly twice per day for 15 minutes each, 5 days per week.  Overall, 
weight loss was minimal in both weight groups.  Participants in the continuous group 
experienced a 2.1% decrease in weight from baseline compared to a 1.0% decrease in the 
intermittent group. Due to the small sample size and sample limitation to women only 
with moderate obesity, the study may not be generalizable to other populations. The 
amount of weight loss seen in this study is comparable to a recent meta-analysis by 
Thorogood et al. (2011) that evaluated the effect of isolated aerobic exercise programs on 
weight loss in overweight and obese populations. In 14 randomized controlled trials 
involving 1847 total subjects, researchers found that moderate-intensity aerobic exercise 
programs of 6-12 months induced only a modest reduction in weight, averaging a 
weighted mean difference of -1.6kg of weight loss for 6-month programs and -1.7 kg for 
12-month programs. The results of the meta-analysis were limited by the lack of 
homogeneity between the included studies. Differences in study populations and exercise 
interventions may have provided inconsistent data, which could have altered the overall 
weight reduction seen in the pooled analysis.  
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 Frequently recommended lifestyle modifications used in weight loss counseling 
have shown only modest results. While exercise alone may not be an appropriate 
intervention for significant weight reduction, dietary restriction often leads to weight 
regain due to changes in energy expenditure and hormonal signals induced by weight 
loss.  
Weight loss counseling 
 
 Although assessment and management of obesity is indicated according to clinical 
guidelines, many health care providers are not consistently recommending weight loss 
interventions to all overweight and obese patients. Several studies have identified that 
obesity care, including diagnosis varies depending on patient characteristics.  
 In the 2011 study by Bleich et al., a secondary aim was to identify physician, 
sociodemographic, and clinical encounter characteristics associated with patients’ 
reception of an obesity diagnosis and weight-related counseling. Researchers found that 
women, young adults aged 18-29, and severely/morbidly obese individuals were 
significantly more likely to receive an obesity diagnosis. Individuals receiving an obesity 
diagnosis were nearly 6 times more likely to receive weight-reduction counseling, nearly 
3 times more likely to receive diet counseling, and 2.5 times more likely to receive 
exercise counseling when compared to those without a formal obesity diagnosis. 
Additional predictors of weight-loss counseling included seeing a cardiologist/other 
internal medicine specialist, having a preventive visit, or more time spent with the 
physician.  
 Dutton and colleagues (2014) examined the association between patient 
characteristics, physician characteristics, and the physician-patient relationship and the 
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likelihood of weight loss counseling by primary care physicians. The cross-sectional 
study collected data through a self-reported survey of primary care patients (n = 143) 
with obesity (mean BMI: 36.9kg/m2). Researchers found that a higher BMI (>35kg/m2), 
more medical conditions, and having a female physician were associated with receiving 
more frequent weight loss counseling. Frequency of physician visits and duration of 
physician-patient relationship were not associated with the amount of weight loss 
counseling received. Similarly, Simkin-Silverman et al. (2005) retrospectively examined 
data from the Primary Care Weight Control Project to identify predictors of obesity 
identification and weight control advice. Body mass index was a strong predictor of 
receiving an obesity diagnosis. Factors associated with receiving weight control advice 
included a history of type 2 diabetes, hypertension, high cholesterol, and arthritis, 
patients’ readiness to change (preparation/action/maintenance), and number of past visits. 
Body mass index and waist circumference were significant univariate predictors of 
weight control advice, but no longer significant in multivariable models most likely 
attributed to the variance associated with diabetes and other risk factors.  
 In summary, the literature regarding patient characteristics and predictors for 
weight related counseling is inconsistent. Patient BMI, obesity co-morbidities, and 
frequency of visits/time spent with the health care provider appear to be factors 
associated with receipt of weight loss counseling in primary care settings. Understanding 
predictors for weight management may influence intervention choice when providing 
obesity care and management.  
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Barriers to weight loss counseling  
 Several barriers have been identified in the literature regarding weight loss 
counseling in primary care settings. Conversely, there was limited research examining 
specific barriers related to prescribing weight loss medications. As both counseling and 
prescribing pertain to obesity management, several barriers may in fact overlap.  
 Gunther, Guo, Sinfield, Rogers, and Baker (2012) conducted interviews with 
general practitioners, practice nurses, and overweight or obese patients to explore barriers 
for implementing specific guidelines in the management of adult obesity in general 
practice. Health care provider barriers identified included a reluctance to take 
responsibility for implementing obesity guidelines, lack of consistency in weight 
management approaches across practices, lack of counseling skills, limited time with 
patients, perceived lack of available services (psychological/nutritional), and restraints 
imposed by commissioners of health. Huang et al. (2004) discussed barriers identified by 
physicians in focus groups. Physician pessimism about patient’s desire and ability to lose 
weight, pessimism about the effectiveness of weight loss counseling, lack of 
comprehensive obesity management resources, insufficient time due to high patient 
volume, underuse of dieticians or lack of experience working with dieticians, lack of skill 
in providing brief counseling, and insufficient knowledge of best clinical practices were 
recognized. The study found a significant barrier was physicians’ feelings of being 
inadequately prepared to provide diet, exercise, and weight loss counseling. This suggests 
that health care providers may have insufficient confidence, resources, and/or a lack of 
knowledge regarding when medications might be indicated as well as their beneficial 
effects.  
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Forman-Hoffman, Little, and Wahls (2006) identified barriers to effectively 
managing obesity in the Veteran’s Health Administration (VHA) primary care settings. 
The most strongly related barrier to providing diet and exercise counseling was poor 
obesity education during medical school and residency training. A lack of information 
provided by the VHA to primary care clinicians and their patients regarding available 
services for weight management was also perceived as a significant barrier. Additionally, 
health care clinician attitudes may also be a barrier to weight loss counseling. For 
example, the researchers also looked at whether clinicians counsel obese patients in a 
positive or negative context. They found that clinicians who believe obesity is a disease 
are more likely to counsel in a positive context compared to those who do not believe it is 
a disease. Perceived barriers in the VHA may differ from other health care settings due to 
differing policies, insurance coverage, and patient population. However, the study 
findings provide insight that negative attitudes impact weight loss counseling and might 
therefore influence intervention choice, including prescribing anti-obesity medication.  
 In summary, a wide range of barriers to weight loss counseling exists. Lack of 
appropriate training, skills, and available resources was consistently demonstrated across 
the literature. Barriers were associated with weight loss counseling as it pertained to diet 
and exercise, and did not specifically include barriers around the use of pharmacologic 
treatment options.  
Available weight loss medications, efficacy, & safety  
 Nine medications are currently Food and Drug Administration (FDA) approved 
for weight loss in the management of obesity. These agents are used as adjunct therapy to 
lifestyle interventions and are typically reserved for individuals unable to lose weight 
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with diet and physical activity alone and for those at greater health risk due to co-morbid 
complications associated with obesity.   
 Pharmacotherapies approved for long-term therapy are classified based on their 
targeted location of action. Centrally acting agents include lorcaserin (Belviq™), 
phentermine/topiramate (Qsymia™), and buproprion/naltrexone (Contrave™, 
Mysimba™). Peripherally acting agents include orlistat (Xenical™) and liraglutide 
(Saxenda™). Four centrally acting amphetamine derivatives are also available for short-
term use (≤12 weeks) including phentermine, benzphetamine, phendimetrazine, and 
diethylpropion. Differences between mechanisms of action exist between agents. 
However, anti-obesity medications may interfere with the physiological mechanisms 
induced by lifestyle interventions that promote weight gain and challenge long-term 
maintenance. All agents produce their effects by reducing food intake or nutrient 
absorption and/or increasing resting or activity-related energy expenditure (Jones & 
Bloom, 2015).   
Overall, anti-obesity medications have shown higher efficacy in producing weight 
loss than lifestyle interventions alone. A review by Yanovski and Yanovski (2014) found 
that long-term obesity medications produced significant weight loss when used in 
combination with lifestyle modifications such as diet and exercise. Compared to placebo, 
additional weight loss at 1 year ranged from approximately 3% of baseline weight with 
orlistat and lorcaserin, to 9% with high-dose pherntermine/topiramate extended release 
(ER). Several randomized controlled trials looking at anti-obesity drugs compared to 
standard care have resulted in 5-10% weight loss when combined with lifestyle 
interventions. For example, Gadde et al. (2011) assessed the efficacy of two doses of 
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combined phentermine plus topiramate ER as an adjunct to diet and lifestyle modification 
for weight loss in obese subjects (n=2487). Both doses resulted in greater efficacy 
compared to placebo (lifestyle intervention alone). At least 5% weight loss was achieved 
in only 21% of the placebo group compared to 62% of patients prescribed phentermine 
7.5mg plus topiramate 46.0mg and 70% prescribed phentermine 15.0mg plus topiramate 
92.0mg. Correspondingly, 7%, 37%, and 48% achieved ≥10% weight loss with the same 
interventions. All groups received standardized counseling for diet and lifestyle 
modification. The study was limited by its generalizability due to restriction of BMI (45 
kg/m^2) and lack of ethnic (86% white) and gender (70% female) diversity.  
As with all medications, anti-obesity agents can be accompanied by adverse 
events. Several of the agents recently approved for long-term use (since 2012) have been 
prescribed independently under other indications for many years and thus adverse side 
effects have been well established. These medications include buproprion, naltrexone, 
phentermine, topiramate, and liraglutide. In addition to studying efficacy, multiple 
randomized controlled trials have included assessment of drug safety profiles. For 
example, Smith et al. (2010) evaluated safety of lorcaserin as an outcome variable for 
weight loss and maintenance, including rates of valvulopathy development. The rate of 
cardiac valvulopathy was not increased among 2472 patients evaluated at year one and 
1127 patients evaluated at year two. Its selective nature of serotonin 2C receptors is not 
generally associated with the valvulopathy previously seen with serotonin 2B receptors, 
although long-term data is not yet established.  
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In summary, several randomized controlled trials have analyzed both safety and 
efficacy of weight loss medications. They concluded that prescribing should be 
individualized and based on a balance between risk and benefit profiles.  
Current practice patterns around weight loss medication use 
Few published studies that have examined weight loss counseling include the use 
of weight loss medications. Ferrante, Piasecki, Ohman-Strickland, and Crabtree (2012) 
studied family physicians’ practice patterns and attitudes regarding extremely obese 
patients and associating factors, including physician knowledge and demographic 
characteristics. Practicing family physicians (n =255) in New Jersey completed self-
administered surveys inquiring about knowledge regarding care of extremely obese 
patients, weight management approaches, attitudes toward managing obesity, challenges 
with physical examinations, availability of supplies, and strategies to improve care. The 
most frequently recommended interventions included basic good nutrition/adding fruits 
and vegetables (81.4% of physicians almost always recommended) and regular exercise 
(79.2% of physicians almost always recommended). Conversely, 46.4% of respondents 
reported almost never recommending weight loss drugs. Higher self-reported knowledge 
about weight loss drugs was associated with more frequent weight loss drug 
recommendations. Physicians with more than 7% of extremely obese patients in practice 
were less likely to recommend weight loss medications compared to those with less than 
7% of extremely obese patients. The self-reported nature of the study may have biased 
results by over or underestimating practice patterns. Response bias may have also 
impacted study findings, as responders may have been more interested in obesity than 
those not responding; thus the results may not represent the general population.  
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Glauser et al. (2015) explored the knowledge and practice patterns of primary 
care physicians (PCPs), endocrinologists (ENDOs), cardiologists (CARDs) and 
bariatricians (BARIs) regarding obesity screening and management. A random-sample of 
300 United States-based practicing physicians completed case vignette surveys tailored to 
their specialty. Self-reported demographic and practice information was also collected. 
On average one-third of PCPs and CARDs’ patients were obese compared with 46% for 
ENDOs and 75% for BARIs. Based on a case vignette presented to participants 
describing an obese patient with multiple comorbidities and risk factors, BMI ≥30kg/m2 
was the most selected indication for weight loss medication across all physician groups. 
Expectations regarding the percentage of expected weight loss for a given case were 
inconsistent. A considerable amount of physicians selected a 15% expected weight loss 
(PCPs 32%, ENDOs 21%, CARDs 36%) with a serotonin 2c receptor agonist, which is 
10% more than what has been demonstrated in the literature. All groups of physicians did 
not perceive the available weight loss medications to be safe or effective. The cases were 
not inclusive of all patient demographics, comorbidities, medical and personal histories 
of which the physician may encounter in clinical practice and therefore may have altered 
responses and study results. However, this suggests that physicians may lack the 
necessary knowledge to effectively utilize weight loss agents in clinical practice. 
In summary, studies that look at practice patterns related to pharmacological 
interventions are limited. Within the available studies, the underlying influences around 
prescribing weight loss medications have not been fully examined. Additionally, the 
literature has focused primarily on physician prescribers and has not evaluated 
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prescribing practices among other prescribers including physician assistants and nurse 
practitioners.   
Summary 
 Weight loss interventions include lifestyle modifications, pharmacotherapy, and 
surgery. Currently, counseling in primary care settings is largely focused on lifestyle 
modifications. Although a combination of diet and exercise may be an effective 
intervention for initial weight loss, weight regain is prevalent and to some extent, a 
function of internal homeostatic changes that stimulate appetite. While the majority of 
studies have found that when health care providers do provide weight loss counseling to 
obese patients, pharmacological approaches are rarely included with their typical 
recommendations of diet and exercise. Five FDA approved weight loss medications have 
demonstrated to be effective approaches to overcoming long-term challenges with weight 
loss maintenance in obese individuals. While safety profiles of weight loss medications 
have been a significant concern in the past, several of the new medications approved have 
been used for many years under alternative indications and without serious adverse 
events.  
Current practice patterns around the use of weight loss counseling, including 
patient characteristics associated with the initiation of counseling and barriers preventing 
consistent counseling were examined in the literature review. While many of these 
factors may be similar, limited research is available regarding the prescribing patterns of 
anti-obesity medications. Four new agents have been FDA approved for long-term use 
since 2012. With the high prevalence of obesity in America, it is essential that providers 
are aware of all effective interventions for obesity management. Understanding provider 
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practices and barriers around the use of these anti-obesity agents may provide insight 
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Provider Attitudes and Practice Patterns of Obesity  
Management with Pharmacotherapy 
Abstract 
Background and Purpose: More than one-third of American adults are obese. 
The prevalence of extreme obesity is rapidly rising. Nine medications are currently 
approved for weight loss yet they remain under utilized with the focus primarily on 
lifestyle modifications. The study’s objective was to determine current prescribing 
patterns and attitudes of weight loss medications in the management of obesity among 
primary care providers (PCPs).   
Methods: PCPs were surveyed to determine practice patterns, attitudes, barriers, 
and facilitators for prescribing weight loss medications.    
Conclusions: A total of 105 surveys were completed. 76% of all PCPs did not 
prescribe weight loss medications for long-term weight loss therapy and 58% of PCPs 
had negative perceptions of pharmacotherapy as a treatment. Significant differences 
existed between prescribing patterns and attitudes of advanced practice clinicians and 
physicians. Safety concerns were identified as the greatest barrier. Having 2+ 
comorbidities and severe obesity were identified as facilitators for prescribing weight loss 
medications. Under utilization of pharmacotherapy suggests that PCPs may not have 
sufficient knowledge about medication safety profiles and efficacy. Delaying treatment 
until patients have reached a high level of morbidity may be less efficacious than earlier 
treatment. 
Implications for Practice: Education regarding effectiveness and risks of weight 
loss medications for obesity management is needed and earlier interventions with 
pharmacotherapy may prevent significant morbidity and mortality.  
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Introduction 
 
The prevalence of obesity in the United States (U.S.) is high. In 2011-2012, 35%, 
or 78.6 million American adults were obese (Ogden, Carroll, Kit, & Flegal, 2014). 
Although there have been no significant changes in obesity prevalence since 2003-2004, 
those living with obesity remains at an all-time high. Alarmingly, the prevalence of 
extreme obesity (body mass index [BMI] ≥40 kg/m2) increased by 70% between 2000 
and 2010 (Sturm & Hattori, 2013).  
The direct and indirect costs attributed to obesity in the U.S. are staggering. While 
direct medical costs may include prevention, diagnostic, and treatment services 
associated with obesity and obesity-related diseases, indirect medical costs may include 
premature mortality, higher disability insurance premiums, and productivity loss due to 
obesity (Hammond & Levine, 2010). According to Finkelstein, Trogdon, Cohen, & Dietz 
(2009), the estimated annual medical cost attributable to obesity in the U.S. was $147 
billion. Overall, the annual medical burden of obesity has risen to almost 10 percent of all 
medical spending (Finkelstein et al., 2009). 
Obesity is a significant health concern. The disease substantially increases the risk 
of morbidity and mortality due to the wide range of associated co-morbidities. According 
to the Centers for Disease Control (CDC), obesity-related conditions comprise some of 
the leading causes of preventable death, including cardiovascular disease, stroke, type 2 
diabetes, and certain types of cancer (CDC, 2016a). Overall, as BMI rises, the risk of 
multi-morbidity (co-occurrence of multiple long-term diseases) increases in both men and 
women. The prevalence of multi-morbidity in men and women with normal weight is 
23% and 28% respectively, rising to 44% in men and 51% in women with extreme 
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obesity (Booth, Prevost, & Gulliford, 2014). Weight loss of 5-10% of total baseline body 
weight has been shown to decrease cardiovascular disease risk factors, including 
lowering blood pressure and blood cholesterol, as well as preventing or delaying the 
development of type 2 diabetes by reducing blood sugars (CDC, 2016b).  
Despite the concerning obesity epidemic, appropriate and consistent management 
of obese individuals in primary care settings remains varied (Bleich, 2011; Shiffman, 
2009). Current clinical guidelines from the U.S. Preventive Services Task Force 
recommend that all adult patients be screened for obesity and individuals with BMI 
≥30kg/m2 should be offered or referred to intensive, multicomponent behavioral 
interventions (Moyer, 2012). Regardless of these recommendations, several cross-
sectional studies have shown that not only are obese individuals not being consistently 
diagnosed, weight loss counseling by primary care providers (PCPs) is also infrequent, 
inconsistent, and sub-optimal (Bleich, 2011, Shiffman, 2009; Smith 2011). When weight 
loss counseling is incorporated into clinical practice, studies have found that lifestyle 
interventions are the foundation of PCP’s recommendations. Although pharmacotherapy 
and bariatric surgery are available and effective weight loss interventions, they are often 
not included or rarely recommended to individuals with obesity (Ferrante, 2012; 
Shiffman, 2009).  
Lifestyle interventions alone are not particularly successful in providing long-
term weight maintenance due to behavioral and environmental pressures as well as 
biological mechanisms induced by weight loss (Korner, 2003; Rosenbaum, 2008). 
Although many individuals are able to lose weight initially with diet and exercise, more 
than one-third of weight lost is regained within year one (MacLean, Bergouignan, 
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Cornier, & Jackman, 2011).	  The U.S. Food and Drug Administration (FDA) have 
currently approved five medications for long-term weight loss therapy. The addition of 
pharmacotherapy as an adjunct to traditional lifestyle approaches has shown to be an 
effective treatment option for weight loss in obese individuals (Khera, 2016; Yanovski, 
2014). When combined with lifestyle interventions, weight loss medications have 
resulted in clinically significant weight loss of 5-10% (Gadde, 2011, Khera, 2016, Smith 
2010; Yanovski, 2014).  
Obesity management and weight loss counseling generally begin in the primary 
care setting. While prior studies have examined factors influencing and barriers 
preventing weight loss counseling in primary care, little research has assessed PCP’s 
practice patterns and attitudes around the use of weight loss medications. There is lack of 
current research examining the underlying reasons for limited pharmacotherapy use in 
weight loss counseling, despite its demonstrated efficacy. Our objective was to determine 
current prescribing patterns and attitudes of weight loss medications in the management 
of obesity among PCPs. Our aims included 1.) To determine why PCPs are or are not 
including weight loss medications in weight loss counseling, 2.) To determine what 
barriers exist around the use of weight loss medications in obesity management, and 3.) 
To determine under what circumstances PCPs are prescribing weight loss medications for 
obesity. 
Study design and methods 
 
 This study was reviewed and approved by the Internal Review Board prior to 
study procedures. Inclusion criteria consisted of the ability to read and write in English, 
self-identified as a PCP, and provided health care for individuals who are ≥18 years of 
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age. Exclusion criteria included PCPs who provided patient care in specialty practices 
that included bariatric health, endocrinology, and/or cardiology. 
Data collection 
 A convenience sample of primary care nurse practitioners (NPs), physician 
assistants (PAs), and physicians (MDs) were recruited using online list-serves from 
regional professional organizations and on-site at one organization’s annual conference in 
Northeastern, U.S. Potential participants during on-site data collection received a hard 
copy invitation and survey and potential online participants received an electronic 
invitation and survey. Participants’ completion of the distributed survey served as passive 
informed consent. Data was entered into LimeSurvey statistical software (version 2.55). 
Survey development 
The study survey was formulated and adapted based on a review of the literature 
reflecting current obesity management and barriers and facilitators for weight loss 
counseling. Two content experts reviewed the survey to ensure clarity and content 
validity. The survey contained 24 questions in which PCPs were asked to express their 
impressions and use of obesity pharmacotherapy (Appendix B). Demographic data 
including ethnicity, type of PCP (i.e. nurse practitioner, physician, or physician assistant), 
years in practice, primary specialty, patient population, and location of clinical practice 
were collected.  
Analysis 
 
PCP demographics were summarized using descriptive statistics and frequency 
tables. Inferential statistics were computed to assess attitudes and practice patterns around 
the use of weight loss medications. Pearson chi-square tests were computed to determine 
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between group (physician vs. advanced practice clinician) differences in demographics, 
attitudes, and practice patterns. McNemar tests were used to compare the recommended 
use of each weight loss medication to its effectiveness. Open ended-questions were 
transcribed using categorical data. For all analyses, a P-value of <0.05, two-sided, was 




The survey reached approximately 964 PCPs. Of the nearly 964 PCPs 
approached, 105 PCPs completed the survey, resulting in a response rate of 
approximately 11%. Eleven of the respondents did not meet the study inclusion criteria, 
resulting in a final n=94. The 94 respondents were self-identified as PCPs who worked 
primarily in family practice, internal medicine, adult primary care, and women’s health. 
The demographic and practice characteristics of the respondents are summarized in Table 
1. Of the 94 respondents, 46 were MDs, 43 were NPs, and 5 were PAs. Due to the low 
response rate of PAs, responses from NPs and PAs were combined to a single provider 
group identified as advanced practice clinicians (APCs) (n=48).  
Provider practice patterns around the use of weight loss medications for obesity 
management  
 
Overall, 60% of the PCPs surveyed reported not prescribing weight loss 
medications for short-term weight loss therapy (<3 months). When grouped by provider 
type, APCs (46%) were prescribing weight loss medication more frequently than MDs 
(33%). 76% of PCPs reported not prescribing weight loss medications for long-term 
therapy (≥3 months). Prescribing patterns were not statistically different between 
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provider groups for long-term therapy. Recommended medications are outlined in Table 
2 in order based on frequency of prescribing.  
 Provider attitudes of weight loss medications as a treatment for obesity 
58% of all PCPs reported “negative” and “very negative” impressions of 
pharmacotherapy as a treatment for obesity. 58% of APCs had a “neutral” to “very 
positive” impression of weight loss medications compared to 20% of MDs (P=0.002). 
75% of MDs had a negative impression. 4% of all PCPs felt weight loss medications 
were safe. 52% of PCPs reported that some medications were safe and others were not 
safe. 73% of APCs expected a >5% weight loss with the use of pharmacotherapy as an 
adjunct to lifestyle interventions compared to 50% of MDs (P=0.044). Weight loss 
medications perceived as effective are outlined in Table 2. While 40% of PCPs reported 
recommending orlistat, only 19% of PCPs reported orlistat as being effective for weight 
loss (Figure 1).  
Perceived barriers to the use of weight loss medications 
 
The most frequently reported factors preventing PCPs from prescribing weight 
loss medications included fear of adverse events followed by fear of medication 
interactions (Table 3). Cost and insurance coverage and lack of perceived effectiveness 
were third. Lack of time was the least important barrier to prescribing. 60% of PCPs 
reported that concern of medication adverse events was a barrier to prescribing weight 
loss medications. 49% of PCPs reported that they would still not prescribe weight loss 
medications even if cost and insurance coverage were not significant barriers. There was 
a significant difference in responses between PCP types. 67% of APCs reported they 
would prescribe if cost/insurance were not barriers, compared to 34% of MDs (P = 0.02).  
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Perceived facilitators to the use of weight loss medications  
 
The most frequently reported circumstance for recommending weight loss 
medication was if patients had 2+ comorbidities associated with obesity. The second 
most frequently reported circumstance was if patients had severe obesity (BMI ≥40 
kg/m2) (Table 4).  Failure to achieve goal weight with lifestyle interventions was third. 




 Regardless of the high prevalence of obesity in the U.S. and its wide range of 
associated co-morbidities, the PCPs in our study were hesitant to prescribe weight loss 
medications, particularly for long-term therapy. In general, over half of the PCPs had an 
overall unfavorable impression of pharmacotherapy as a treatment option for obesity, 
with MDs having a more negative impression than APCs. This, in addition to safety 
concerns and cost/insurance factors may explain why prescribing is low among all PCP 
types.  
Safety concerns were the most important barriers preventing PCPs from 
prescribing weight loss medications. Although long-term safety data has not been 
established for the combined agents approved for weight loss therapy, several drugs have 
been prescribed independently for many years; thus adverse side effects have been well 
established. Randomized controlled trials have examined drug efficacy and safety 
profiles. Reported common adverse side effects included gastrointestinal upset, 
neurological complaints (i.e. headache, dizziness, tremor; paresthesias), hypoglycemia, 
and elevated heart rate (Yanovski, 2014; Khera, 2016). Serious adverse events were 
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infrequently reported, comparable to placebo, varied depending on drug type, and 
included conditions such as cholelithiasis, cholecystitis, pancreatitis, severe 
hypoglycemia, and valvulopathy (Khera et al., 2016). Though long-term trials have not 
been established, cardiac valvulopathy is generally associated with serotonin 2B receptor 
medications as opposed to the more selective serotonin 2C receptor medications recently 
approved (Smith et al., 2010). While weight loss medications may impose risk, obesity is 
associated with significantly higher all-cause mortality relative to normal weight (Flegal, 
Kit, Orpana, & Graubard, 2013). Thus, adverse effects of medications should be weighed 
against the benefits seen with weight loss medications. The PCPs’ concerns about safety 
in the current study support previous research findings where physicians did not perceive 
available weight loss medications to be safe or effective (Glauser et al., 2015). This 
suggests that PCPs may not have sufficient knowledge regarding the safety profiles of 
available medication options. Education of PCPs regarding the drugs’ pharmacodynamics 
as well as risks for adverse side effects may facilitate increased confidence for 
prescribing, thus improving weight loss in obese patients. 
Our results demonstrated that PCPs were more likely to prescribe weight loss 
medications to patients who were severely obese than to patients who were moderately or 
mildly obese. This is contrary to previous research, which found that physicians who 
cared for >7% extremely obese patients were less likely to recommend weight loss 
medications compared to those who cared for <7% extremely obese patients (Ferrante et 
al., 2009). Conversely, although not specific to pharmacotherapy, our findings were 
consistent with previous studies that have reported BMI as a key factor in providing 
weight loss counseling to patients. Bleich et al. (2011) found that severely/morbidly 
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obese individuals were significantly more likely to receive an obesity diagnosis and 
therefore were nearly 6 times more likely to receive weight-reduction counseling than 
those who did not receive a diagnosis. Dutton et al. (2014) also found that a higher BMI 
(>35 kg/m2) was associated with receiving more frequent weight loss counseling. 
According to our findings, it was evident that the degree of obesity was a pertinent factor 
for prescribing medication. There was a direct relationship between weight severity and 
increased prescribing. Obese patients who are not classified as severely obese may not be 
receiving recommendations from their PCPs about all available and effective treatment 
options, including pharmacotherapy. Further education of PCPs regarding when to 
initiate conversations with patients about weight loss pharmacotherapy, to include all 
levels of obesity, may lead to earlier interventions and prevention of worsening obesity 
and co-morbid disease.   
A modest 5-10% weight reduction has been shown to improve lipids, decrease 
blood pressure, and reduce HbA1c in patients with obesity (Wing et al., 2011). A 
systematic review showed that weight loss medications produced greater improvements 
in cardiometabolic risk factors than behavioral interventions alone (Yanovski & 
Yanovski, 2014). Other studies have shown that weight loss medications resulted in a 
more pronounced improvement in blood pressure, lipids, and glycemic control when used 
for patients with pre-existing co-morbid disease (Gadde, 2011). Weight loss medications 
are approved for patients with a BMI of ≥30 kg/m2 or a BMI ≥ 27 kg/m2 with one or 
more co-morbidity in conjunction with a reduced-calorie diet and increased physical 
activity. The present study found that the most important facilitator for prescribing 
weight loss medications was patients’ having two or more associated co-morbidities. 
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These findings suggest that PCPs may be intervening too late, when patients have 
reached the “severely obese” category and have already developed multiple co-
morbidities. Recommending and prescribing weight loss medications earlier in the 
disease process may be a more proactive approach to preventing the long-term sequelae 
of obesity.  
Despite the overall low prescribing patterns for both short-term and long-term 
weight loss therapy among all PCPs, APCs prescribed medication more frequently than 
MDs and were significantly more likely to prescribe medication when cost and insurance 
coverage were not pertinent factors. APCs also had a significantly more positive 
impression of pharmacotherapy as a treatment for obesity and higher expectations for 
weight loss than MDs. This suggests that PCPs with a higher expectation for weight loss 
and more positive impression may be more likely to prescribe weight loss medications 
for obesity. Previous research has shown that physicians’ higher self-reported knowledge 
regarding weight loss medications was associated with fewer negative attitudes and more 
frequent recommendations of pharmacotherapy options (Ferrante et al., 2009). With the 
majority of the APC group being NPs, our findings may be attributable to the 
philosophical lens of the nursing discipline. NPs traditionally take a holistic approach to 
patient-centered, context-based, diagnostic reasoning and care planning that is in line 
with nursing theory and philosophy (Burman, Stepans, Jansa, & Steiner, 2002). 
Implementing a holistic approach that is patient-centered and highly individualized can 
be key to producing positive outcomes for patients with obesity.  
We found that PCPs continue to be reluctant to recommend weight loss 
medications, despite their shown efficacy. Overall, anti-obesity medications have shown 
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higher efficacy in producing weight loss than lifestyle interventions alone. A review by 
Yanovski and Yanovski (2014) found that long-term obesity medications produced 
significant weight loss when used in combination with lifestyle modifications such as diet 
and exercise. Compared to placebo, additional weight loss at 1 year ranged from 
approximately 3% of baseline weight to 9%. Similarly a systematic review by Khera et 
al. (2016), found that all five medications approved for long-term weight loss therapy 
achieved at least 5% weight loss at 52 weeks, a significant improvement in weight 
maintenance.  
Obesity management is multifactorial. Our study results suggest that obesity 
management for many patients does not extend past behavioral counseling and 
recommendations for diet and exercise. PCPs may not be appropriately educating their 
patients about the full spectrum of available and effective treatment options for obesity 
management. This may be due to low perceived effectiveness, safety concerns, and 
specific patient characteristics required. When considering the Chronic Care Model 
(Bodenheimer, Wagner, & Grumbach, 2002), patients cannot be fully informed and 
engaged members in the decision-making process if they do not have fully informed and 
engaged PCPs. This study demonstrates the need for increased educational programs for 
PCPs regarding the indications, effectiveness, and potential risks associated with the use 
of weight loss medications. Continuing education may enhance PCP knowledge about 
weight loss medications and improve PCPs’ ability to have informed conversations with 
patients and engage their patients in the decision-making process. Both PCPs and patients 
need accurate information about treatment options to collaboratively weigh the risks with 
the benefits. Additionally, earlier interventions with pharmacotherapy may prevent 
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morbidity and mortality associated with obesity and its co-morbidities. Differences exist 
in prescribing patterns between PCP types. Further research may be needed to better 
understand these differences in PCP attitudes and prescribing patterns. 
Limitations 
The current study is primarily limited by the small sample size and low response 
rate. Identifying list-serve numbers can be inexact; thus an exact response rate could not 
be determined. Causal inferences could not be identified. PAs were not well represented 
in the study. Future studies should examine the effect that educational programs, focused 
on weight loss pharmacotherapy, have on PCP prescribing patterns.   
Conclusion 
 This study demonstrates the need for supplementary educational programs to 
cultivate informed PCPs about the safe and effective use of weight loss medications as a 
component to obesity management. Educated PCPs can better inform and engage patients 
in shared decision-making with regards to obesity management. The overarching goal of 
PCPs is to reduce poor health outcomes and improve quality of life. Earlier use of 
pharmacotherapy in combination with lifestyle modifications may reduce the costly 
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Table 1: PCP demographic characteristics 
 
Characteristic:    Respondents n (%):  
Profession: 
 Nurse practitioner   43 (46) 
 Physician Assistant   5 (5) 
 Physician     46 (49) 
Primary specialty: 
 Family Practice/Family Medicine 52 (56) 
 Internal Medicine    21 (23) 
 Adult Primary Care   11 (12) 
 Women’s Health   3 (3) 
 Other     6 (7) 
Years in practice: 
 0-10     35 (37) 
 11-20     27 (29) 
 ≥20     32 (34) 
Practice type: 
 Solo     3 (4) 
 Group      44 (53) 
 Teaching hospital practice  36 (43) 
Practice location: 
 Rural     36 (53) 
 Urban     32 (47) 
% Of patient population ≥18 years old: 
 About 50%    3 (3) 
 Greater than 50%   88 (94)  
 Less than 50%    3 (3) 
Average patient contact hours: 
 0-10     7 (8) 
 11-20     17 (18) 
 21-30     27 (29) 
 31-40     39 (43) 
 >40     2 (2) 
Percent of patient population overweight/obese: 
 0-25%     2 (2)  
 26-50%    42 (45) 
 51-75%    43 (46) 
 76-100%    3 (3) 
Race/ethnicity: 
 White     87 (93) 
 Black or African American  0 (0) 
 Hispanic or Latino   5 (5) 
 Asian     1 (1) 
 Native Hawaiian   0 (0) 
 American Indian   1 (1) 
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Table 2: Recommended medications and perceived effectiveness 
 
Medication Recommended (%) Perceived Effective (%) 
Orlistat 40 19 
Phentermine 30 21 
Phentermine/topiramate 27 33 
Lorcaserin  12 13 
Buproprion/naltrexone 12 21 
Liraglutide 9  13 
Diethylpropion 2 1  
Benzphetamine 0  2  
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MDs (n) P value 
Fear of adverse events 91 47 44 0.963 
Fear of medication 
interactions 
83 45 38 0.322 
Cost/insurance coverage 78 41 37 0.346 
Lack of perceived 
effectiveness 
78 34 44 0.001 
Lack of patient motivation 72 40 32 0.104 
Insufficient knowledge about 
available medication options 
68 38 30 0.042 
Insufficient knowledge about 
current 
guidelines/recommendations 
62 35 27 0.156 
Lack of available resources 
for prescribing weight loss 
medications 
53 29 24 0.198 
Lack of training & skill 
related to overall obesity 
management 
44 28 16 0.007 
Lack of time 22 14 8 0.107 	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APCs (n) MDs (n) P value 
Patient has 2+ co-
morbidities associated 
with obesity 
82 45 37 0.039 
Patient is severely obese 
(BMI 40 kg/m2 or above) 
81 45 36 0.036 
Patient has failed to 
achieve goal weight with 
lifestyle interventions 
alone 
78 45 33 0.008 
Patient requests 
medication 
77 43 34 0.076 
Insurance coverage 75 42 33 0.242 
Patient has 1 co-morbidity 
associated with obesity 
71 40 31 0.070 
Patient is moderately 
obese (BMI 35-39.9 
kg/m2) 
67 39 28 0.068 
Patient is mildly obese 
(BMI 30-34.9 kg/m2) 
32 21 11 0.057 	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APPENDIX A 
Research Information Sheet 
 
Title of Study: Provider Attitudes and Practice Patterns of Obesity Management 
with Pharmacotherapy 
 
Principal Investigator (PI): Brittany Granara, RN 
 
Faculty Sponsor: Dr. Jennifer Laurent, PhD, APRN 
 
Funder: College of Nursing and Health Sciences 
 
Introduction:  
You are being invited to take part in this research study because you are a licensed, 
practicing health care provider in the state of Vermont. This study is being conducted by 
Brittany Granara, RN, in conjunction with Dr. Jennifer Laurent, PhD, APRN, at the 
University of Vermont. 
 
Purpose 
The primary purpose of this study is to determine current prescribing patterns among 
primary care providers of Food and Drug Administration (FDA) approved weight loss 
medications in the management of obesity. The study has three aims including, 1.) To 
determine why providers are or are not including weight loss medications in weight loss 
counseling, 2.) To determine what barriers exist around the use of weight loss 
medications in obesity management, and 3.) To determine under what circumstances 
providers are prescribing weight loss medications for obesity.  
 
Study Procedures 
If you choose to take part in the study, you will be asked to complete a one-time pen and 
paper and/or electronic survey. This survey is expected to take no longer than 10 minutes 
to complete. Questions on the survey include demographic information, current 
knowledge around available weight loss medications, current practice patterns around the 
use of weight loss medications, and barriers preventing the use of weight loss 
medications.  
 
Some of the survey questions related to obesity pharmacotherapy may be familiar to you 
and others may not. No judgments about individual practice competency or skill will be 
made from the survey responses and there are no correct or incorrect answers to the 
questions being asked.  
 
Benefits 
By participating in this current research study, there may not be any direct benefit for 
you. However, information deemed from this study may benefit you and other health care 
providers in the future.  
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Risks 




No costs will be required of you for participating in this research study 
 
Compensation 
Should you choose to participate, you will receive a raffle ticket upon completion of the 
survey to be entered into a lottery with your preferred contact information. One raffle 
number at your conference will be selected to receive a $20 equivalent VISA gift card. If 
you are completing the online electronic survey, an additional separate hyperlink will be 
provided to you upon completion of the survey for you to enter your email information 
into the online raffle.  
 
Confidentiality 
All personal demographic information collected about you throughout this study will be 




This research study is completely voluntary and you are not required to participate in this 
survey. You are not required to complete every survey question to remain in the study, 
and you may withdraw from the study at any point during the completion of the study. 
 
Questions 
If you have any questions about this study at any time, please contact me, Brittany 
Granara, at the following phone number (802) 656-3024. If any questions or concerns 
arise regarding your rights as a research participant, you may contact the Director of the 
Research Protections Office at (802) 656-5040.  
 
Participation 
Participation in the study is voluntary. You may choose to not participate or withdraw 

















Title of Study: Provider Attitudes and Practice Patterns of Obesity Management with 
Pharmacotherapy 
 
Principle Investigator: Brittany Granara, RN 
 








*If answered yes to questions 1-2, please proceed with survey. If no to either question 1 
or 2, please stop here. Thank you for your time 
 
3. What type of practitioner are you? (Please circle one) 
a. Nurse Practitioner 
b. Physician Assistant 
c. Physician 
 
4. What is your primary specialty? ________________  
 
5. How many years have you practiced health care since completing your 
educational requirements? ______________ 
 




7. Please identify what statements best describe your practice 
a. Solo practice 
b. Group practice 
c. Teaching hospital practice 
d. Other: ____________ 
 
8.  What statement best describes your location of practice? 
a. Rural 
b. Urban 
c. Other: ____________ 
 
9. Approximately, what percentage of your patient population is aged ≥18 years? 
a. Approximately 50% 
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b. Greater than 50% 
c. Less than 50% 
 
10. How many patient contact hours do you have per week? ____________ 
 











13. What is your overall impression of pharmacotherapy as a treatment for obesity? 




e. Very negative 
f. Unknown- not familiar with pharmacotherapy for obesity 
 
14. In your opinion, based on your clinical knowledge, currently available 
medications for the treatment of obesity are: 
a. Safe 
b. Somewhat safe 
c. Some medications are safe, others are not 
d. Unsafe 
 
15. Which, if any, medications have you recommended to a patient as a treatment for 
obesity? (Check all that apply) 
o Orlistat (Xenical™) 
o Lorcaserin (Belviq™) 
o Buproprion/naltrexone (Contrave™, Mysimba™) 
o Phentermine/topiramate (Qsymia™) 




o Diethylpropion  
o Other (specify) _____________ 
 
16. Which, if any, medications do you think are effective for weight loss?  
(Check all that apply) 
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o Orlistat (Xenical™) 
o Lorcaserin (Belviq™) 
o Buproprion/naltrexone (Contrave™, Mysimba™) 
o Phentermine/topiramate (Qsymia™) 




o Diethylpropion  
o Other (specify) _____________ 
 
17. How much weight loss would you expect your patients to achieve with 







18. Please indicate whether or not the following factors would be important or not 
important circumstances for recommending pharmacotherapy to your obese 





o  o  Patient requests medication 
 
o  o  Insurance coverage 
 
o  o  Patient has failed to achieve goal weight with 
lifestyle interventions alone 
 
o  o  Patient is mildly obese (BMI 30-34.9 kg/m^2) 
 
o  o  Patient is moderately obese (BMI 35-39.9 
kg/m^2) 
 
o  o  Patient is severely obese (BMI 40 kg/m^2 or 
above) 
 
o  o  Patient has 1 co-morbidity associated with 
obesity (i.e. type II diabetes, hypertension, 
hypercholesterolemia, arthritis, etc.) 
 
o  o  Patient has 2+ co-morbidities associated with 
obesity 
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o  o  Other (please specify):___________________ 
 
19. Please indicate whether or not the following factors would be important or not 
important factors in preventing you from prescribing pharmacotherapy as a 





o  o  Safety concerns- fear of adverse events 
 
o  o  Fear of interaction with other medication 
 
o  o  Cost/insurance coverage 
 
o  o  Lack of perceived effectiveness 
 
o  o  Insufficient knowledge about available 
medication options 
 
o  o  Insufficient knowledge about current 
guidelines and recommendations 
 
o  o  Lack of available resources for prescribing 
weight loss medications 
 
o  o  Lack of training and skill related to overall 
obesity management 
 
o  o  Lack of patient motivation 
 
o  o  Lack of time 
 
o  o  Other (please specify):___________________ 
 
20. If cost and insurance coverage were not barriers, would you then prescribe 




21. Is fear of adverse events preventing you from prescribing weight loss medications 
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22. Do you currently prescribe weight loss medication for short-term weight loss 




23. Do you currently prescribe weight loss medication for long-term weight loss 




24. What is your race/ethnicity? (Check all that apply) 
o White 
o Black or African American 
o Hispanic or Latino 
o Asian 
o Native Hawaiian  
o American Indian 
o Other (specify):_______________ 
 	  
